Clinical Trial Update: Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

View source ↗

Summary

The clinical trial evaluating nab-paclitaxel (Abraxane) for metastatic breast cancer in routine clinical practice has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Celgene Corporation | Conditions: Breast Neoplasms | Status: TERMINATED